Information Provided By: 
Fly News Breaks for February 23, 2016
AMAG
Feb 23, 2016 | 14:07 EDT
Northland analyst David Buck noted that sNDA for single-dose, preservative free Makena had a March PDUFA date so today's approval came earlier than expected and should reduce uncertainty for AMAG. The analyst, who sees the launch of the new version of this drug as a growth driver, reiterates his Outperform rating and $40 price target on AMAG shares, which are up about 2% to $25.73 in afternoon trading.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
